The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Evaluating the prognostic value of CTCs in patients with myeloma enrolled in the PERSEUS trial
Luca Bertamini, MD, Erasmus MC, Rotterdam, Netherlands, discusses a study evaluating the prognostic impact of circulating tumor cells (CTCs) in transplant-eligible patients with multiple myeloma enrolled in the PERSEUS trial (NCT03710603). Dr Bertamini highlights that CTCs demonstrated strong prognostic value independent of other risk factors and should be considered in clinical practice. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
